Breast Cancer Vaccine Shows 97% Success in Early Trial, Predicting End of Chemotherapy by 2030
In a groundbreaking development released today from the University of Oslo, a novel mRNA vaccine targeting triple-negative breast cancer has achieved a 97% success rate in preventing recurrence among high-risk patients. Researchers project that by 2030, this personalized immunotherapy will replace traditional chemotherapy for most breast cancer diagnoses, transforming a grueling, often debilitating treatment into a simple series of shots. The technology, which trains the immune system to hunt and destroy micro-tumors before they spread, is already being fast-tracked for global approval, with leading oncologists hailing it as the beginning of the end for aggressive breast cancer.